Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.

Valentina Agnese, Giuseppe Cicero, Viviana Bazan, Antonio Russo, Maria E. Fratto, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini

Risultato della ricerca: Articlepeer review

14 Citazioni (Scopus)

Abstract

The ubiquitin-proteasome pathway is the main proteolytic system present in the nucleus and cytoplasm of all eukaryotic cells. Apoptosis activation induced by ubiquitin-proteasome pathway inhibition makes the proteasome a new target of anticancer therapy. Bortezomib is the first proteasome inhibitor to be approved by the US FDA; in 2003 as a third line and in 2005 as a second line therapy for the treatment of multiple myeloma only. This review focuses on the use of bortezomib, not only in its therapeutic role but also, more specifically, in its biologic role and discusses the most recent applications of the drug in solid tumors, both at a preclinical and clinical level.
Lingua originaleEnglish
pagine (da-a)1571-1586
Numero di pagine16
RivistaExpert Opinion on Therapeutic Targets
Volume11
Stato di pubblicazionePublished - 2007

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint Entra nei temi di ricerca di 'Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.'. Insieme formano una fingerprint unica.

Cita questo